Market Overview

T1D Exchange Adds Strategic Leadership to Board and Team in Response to Organizational Growth

Share:





T1D
Exchange
, an organization dedicated to accelerating therapies and
improving care in type 1 diabetes, today announced the election of a new
Board member and the addition of three executives to its leadership
team. These additions demonstrate the organization's rapid growth as it
continues to build strategic initiatives that improve outcomes for the
type 1 diabetes community.

Each member brings extensive experience that will help T1D Exchange in
its mission to accelerate therapies and improve care in type 1 diabetes.
T1D Exchange warmly welcomes:

  • David H. de Weese: Mr. de Weese
    joins as the Exchange's newest Board executive. Previously, Mr. de
    Weese is partner at Paul Capital's New York office, where he was
    instrumental in developing Paul Capital's deal origination strategy
    and transaction sourcing network. Mr. de Weese brings extensive
    entrepreneurial experience and in-depth scientific and business
    knowledge to his role as board member.
  • Jaya Plamanabhan: Mr. Plamanabhan
    joins as Chief Technology Officer. Prior to joining T1D Exchange, Mr.
    Plamanabhan served as Acting Chief Technology Officer at Rede App,
    where he advised the CEO and management team on all product and
    technology related matters and served as Chief Data Scientist and VP
    of Engineering at Cure Forward, a platform that connects cancer
    patients with genomic medicine. As Chief Technology Officer, Mr.
    Plamanabhan will craft information-driven strategies to develop an
    integrated quality care and research platform.
  • Nicole Rioles: Ms. Rioles joins
    T1D Exchange as Quality Improvement Director. In her role, she will be
    responsible for the organization's strategic initiative to advance
    clinical care for people living with type 1 diabetes; while reducing
    inefficiencies and cost in delivering care. Ms. Rioles was most
    recently the Prevention & Wellness Trust Fund Director at the Boston
    Public Health Commission. There, she was responsible for leading high
    profile projects to decrease preventable risk factors and illness,
    improve management of chronic disease and eliminate racial and ethnic
    inequities in chronic disease in the City of Boston. She brings over a
    decade of experience helping improve health outcomes for populations
    in need.
  • Jason Dana Costa: Mr. Costa was
    promoted from his role as Chief Financial Officer to Chief Operating
    Officer. Mr. Costa has served as the Exchange's Chief Financial
    Officer for the past three years. In his role, Jason helped secure
    three Helmsley Charitable Trust capacity-building grants between $3 -
    $9MM. In his new role, Jason will oversee the operations of the entire
    organization, ensuring that it's positioned to meet its strategic
    objectives.

"Our growth is a direct result of the impact we are having to improve
outcomes for the type 1 community," said Dana Ball, Executive Director
and Co-founder of T1D Exchange. "To continue to accelerate novel
therapies and improve clinical care takes both leadership and deep
expertise. We are thrilled to grow our team with exceptional talent at
both the Board and senior staff levels. Each individual brings strong
expertise from successful backgrounds in business, healthcare and
technology that will help direct the continued growth and success of our
organization. It is by adding talent that we drive toward improving
outcomes for those living with type 1 diabetes."

To accommodate staff growth, the organization recently expanded the size
of its program office in Boston, Massachusetts.

About T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1
diabetes need better solutions faster – better treatments and better
care. Our nonprofit organization takes an innovative approach that puts
the community of people touched by type 1 diabetes at the center of
research that will meaningfully impact their lives. Our integrated model
offers researchers access to aggregated clinical, biological,
patient-reported outcomes and electronic health record data, all while
fostering collaboration among patients, physicians, researchers and
industry. Our model is multi-faceted and complex, but our goal is
simple: to tangibly improve outcomes for people with type 1 diabetes as
fast as humanly possible.

View Comments and Join the Discussion!
 

Partner Center